Abstract:Data integration methods are used to obtain a unified summary of multiple datasets. For multi-modal data, we propose a computational workflow to jointly analyze datasets from cell lines. The workflow comprises a novel probabilistic data integration method, named POPLS-DA, for multi-omics data. The workflow is motivated by a study on synucleinopathies where transcriptomics, proteomics, and drug screening data are measured in affected LUHMES cell lines and controls. The aim is to highlight potentially druggable pathways and genes involved in synucleinopathies. First, POPLS-DA is used to prioritize genes and proteins that best distinguish cases and controls. For these genes, an integrated interaction network is constructed where the drug screen data is incorporated to highlight druggable genes and pathways in the network. Finally, sfunctional enrichment analyses are performed to identify clusters of synaptic and lysosome-related genes and proteins targeted by the protective drugs. POPLS-DA is compared to other single- and multi-omics approaches. We found that HSPA5 , a member of the heat shock protein 70 family, was one of the most targeted genes by the validated drugs, in particular by AT1-blockers. HSPA5 and AT1-blockers have been previously linked to α -synuclein pathology and Parkinson's disease, showing the relevance of our findings. Our computational workflow identified new directions for therapeutic targets for synucleinopathies. POPLS-DA provided a larger interpretable gene set than other single- and multi-omic approaches. An implementation based on R and markdown is freely available online. We present a computational workflow that combines the analysis of different types of data measured in cell line studies with non-overlapping samples. We apply the workflow to measurements of gene expression, protein abundances, and a screening of a wide range of FDA-approved drugs. These different types of data are obtained from LUHMES brain cells and jointly analyzed to discover new treatment options in synucleinopathies, such as Parkinson's disease. Our workflow includes a new probabilistic method, named POPLS-DA. POPLS-DA combines the analysis of the genes and proteins to pinpoint a set of relevant genes and proteins that can distinguish affected and non-affected cells. Compared to other approaches, POPLS-DA found a larger set of genes relevant to the disease. Further, we constructed a network that connects the relevant genes and proteins that interact with each other. We incorporate the drug screening data to highlight which part of the network is relevant to the disease and druggable. Through additional analysis of the functionality, we discovered that the genes and proteins that are targeted by protective drugs share relevant properties, namely they are synaptic and lysosome-related genes. Notably, we found that specific types of drugs, namely AT1-blockers such as Telmisartan, are protective and target the network of relevant genes and proteins. These drugs are approved by the FDA and readily available to further investigate their potential in treating synucleinopathies. We further found that a gene named HSPA5, a member of the heat shock protein 70 family, is highly targeted by the protective drugs. This gene has been linked to Parkinson's disease in previous scientific literature. Our computational workflow and the implementation in R and markdown are freely available online.

omicSynth: An open multi-omic community resource for identifying druggable targets across neurodegenerative diseases

Network Integration and Protein Structural Binding Analysis of Neurodegeneration-Related Interactome.

Prioritization of Drug Targets for Neurodegenerative Diseases by Integrating Genetic and Proteomic Data From Brain and Blood

Learning good therapeutic targets in ALS, neurodegeneration, using observational studies

An omics perspective on drug target discovery platforms

In Silico Identification of Multi-Target Ligands as Promising Hit Compounds for Neurodegenerative Diseases Drug Development

Genetic insights into drug targets for sporadic Creutzfeldt-Jakob disease: Integrative multi-omics analysis

The Neurodegenerative Disease Knowledge Portal: Propelling Discovery Through the Sharing of Neurodegenerative Disease Genomic Resources

Open science in precision medicine for neurodegenerative diseases

Statistical integration of multi-omics and drug screening data from cell lines

Identification of Novel Drug Targets for Alzheimer's Disease by Integrating Genetics and Proteomes from Brain and Blood.

High-Throughput Screening Platforms in the Discovery of Novel Drugs for Neurodegenerative Diseases

Unexplored Therapeutic Opportunities in the Human Genome

Identification of novel drug targets for Alzheimer’s disease by integrating genetics and proteomes from brain and blood

Identification of Novel Immune-Relevant Drug Target Genes for Alzheimer's Disease by Combining Ontology Inference with Network Analysis.

Identifying compounds to treat opiate use disorder by leveraging multi-omic data integration and multiple drug repurposing databases

Network-based drug repurposing for psychiatric disorders using single-cell genomics

PharmOmics: A species- and tissue-specific drug signature database and gene-network-based drug repositioning tool

Navigating the Gene Co-Expression Network and Drug Repurposing Opportunities for Brain Disorders Associated with Neurocognitive Impairment

Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics – An AI-Enabled Biological Target Discovery Platform

Comorbidity-Guided Text Mining and Omics Pipeline to Identify Candidate Genes and Drugs for Alzheimer's Disease